The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) commenced on October 15, 2025, in Vienna, Austria. During this key event, Sinocare showcased its innovative diabetes management solutions, emphasizing its commitment to improving patient care through advanced technology.
Expert Insights on iCan CGM Performance
Sinocare organized an international symposium featuring prominent figures in diabetes research, including Professor Lori Laffel, Dr. Guido Freckmann, and Professor Julia Mader. They presented their studies involving the iCan™ continuous glucose monitor (CGM), focusing on critical themes such as ‘Performance, Practicality, and Pediatrics.’
Promising data from recent studies conducted in Germany and the United States highlighted the iCan CGM’s effectiveness in both adult and pediatric populations. The symposium also addressed practical considerations for initiating CGM systems in real-world scenarios, drawing on expertise from a leading pediatric diabetes center. Notably, discussions included the technology’s potential influence on travel and employment for individuals living with diabetes, particularly those with ambitions related to aviation.
Global Launch of the iCan i6 CGM System
The spotlight at Sinocare’s exhibition was on the next-generation iCan i6 CGM system, which offers enhanced features for users. This system boasts 15-day accuracy and a more comfortable wear experience, alongside several significant upgrades. These include a one-step application process with a smaller, lighter sensor, support for 27 languages to facilitate global accessibility, and a built-in altitude compensation algorithm that ensures reliable readings at high elevations.
Furthermore, Sinocare’s exclusive partner, A.Menarini Diagnostics s.r.l, presented the co-branded GlucoMen® iCan CGM system at EASD. This collaboration attracted considerable interest from medical professionals, who engaged with the immersive booth experience showcasing the system’s latest features and clinical benefits.
On September 15, prior to the conference, Sinocare held a private dinner seminar to introduce its “A+C” Diabetes Prevention and Control Ecosystem to key stakeholders. This innovative model combines non-invasive screening via AGEscan with CGM technology to enable early risk detection and precision interventions.
Additionally, Sinocare unveiled its hospital glucose management solution, which seamlessly integrates outpatient and inpatient care. This initiative aims to provide an end-to-end digital diabetes management system, enhancing both the efficiency and quality of patient care.
Sinocare’s participation in EASD 2025 reinforced its position as a leader in diabetes management solutions, showcasing the deep integration of technological advancements with clinical needs. The company’s commitment to fostering global collaborations with experts and partners highlights its dedication to improving diabetes care worldwide.
As the conference unfolds, the emphasis remains on Sinocare’s ongoing efforts to innovate and implement practical solutions that can significantly enhance the lives of individuals managing diabetes.
